Tafero-EM (Emtricitabine & Tenofovir Alafenamide) has been approved for use in combination with other antiretroviral agents for the treatment of HIV infection in adults and children 12 years of age and older with a body weight of at least 35 kg.
This drug is new and necessary for the treatment of HIV (Human Immunodeficiency Virus). Tafero-EM differs from its competitors in the absence of negative side effects. The main components that are included in its composition are alafanamide at a dose of 25 milligrams, embrycitabine at a dose of 200 milligrams. It is they that determine the effect of the drug. Tafero-EM is a drug that is taken during ARV therapy in patients with HIV stage 1. An important distinguishing feature of the product is a high level of effectiveness and a minimum of side effects.
The emtricitabine and tenofovir alafenamide regimens were not statistically inferior to those with emtricitabine and tenofovir disoproxil fumarate, based on the percentage of patients with HIV RNA levels less than 50 units / ml. Tests for specific measures of kidney function and bone health have also shown the benefits of the emtricitabine, tenofovir alafenamide (F / TAF) regimen over emtricitabine / tenofovir disoproxil fumarate (F / TDF).